Baseline characteristics

Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas · Source last updated 2017-11-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      12

   units

   Participants

groups

1. description

   MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days. MLN9708

   id

   BG000

   title

   MLN9708

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            55

            upper Limit

            74

            value

            70

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            3

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            9

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            5

         title

         Cutaneous T-cell Lymphoma (CTCL)

      2. measurements

         1. group Id

            BG000

            value

            7

         title

         Peripheral T-cell Lymphoma (PTCL)

   param Type

   COUNT_OF_PARTICIPANTS

   title

   T-Cell Lymphoma Subtype

   unit Of Measure

   Participants

population Description

12 analyzable patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice